Filtered By:
Drug: Pradaxa
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 482 results found since Jan 2013.

Non‐vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
ConclusionsFor the primary outcome, the absolute benefits of NOACs were modest (NNT/year values being large). Reduced hemorrhagic stroke rates with NOACs could be due to superior embolic infarct prevention and fewer consequential hemorrhagic transformations. Among apixaban recipients, the absolute mortality benefit exceeded that for the primary outcome, indicating prevention of additional unrelated deaths. The substantially greater NOAC acquisition costs need viewing against probable greater safety and the avoidance of monitoring bleeding risks.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Cyrus R. Kumana, Bernard M.Y. Cheung, David C.W. Siu, Hung‐Fat Tse, Ian J. Lauder Tags: Unsolicited Review Source Type: research

Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort
Conclusion Phase I of GLORIA-AF shows that VKAs were mostly used in patients with persistent/permanent (vs. paroxysmal) AF and in those with high stroke risk. Furthermore, there were meaningful geographical differences in the use of VKA therapy in the era before the availability of NOACs, including a much lower use of VKAs in China, where most patients either received antiplatelet agents or no antithrombotic treatment.
Source: Europace - August 30, 2016 Category: Cardiology Authors: Huisman, M. V., Ma, C. S., Diener, H.-C., Dubner, S. J., Halperin, J. L., Rothman, K. J., Teutsch, C., Schoof, N., Kleine, E., Bartels, D. B., Lip, G. Y. H., for the GLORIA-AF Investigators Tags: Atrial fibrillation Source Type: research

Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Atrial fibrillation (AF) is a significant risk factor for stroke and peripheral thromboembolic events (TEs). Preventing blood clots in the heart to reduce stroke and TE risk is a key goal of AF therapy. Traditional stroke risk assessment tools for patients with nonvalvular AF include the CHADS2 and CHA(2)DS(2)-VASc scores, while long-term outcome data with the newer direct oral anticoagulants (DOACs) are emerging. The goals of this review were to assess traditional therapies and existing treatment guidelines and to discuss key pharmacologic properties of the DOACS, noting how these may benefit at-risk patients with AF. Thi...
Source: Clinical and Applied Thrombosis/Hemostasis - November 27, 2016 Category: Hematology Authors: Stacy, Z., Richter, S. Tags: Review Source Type: research

Comparing the Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in the Elderly Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
CONCLUSIONS: Compared to warfarin, NOACs were associated with a significantly lower risk of adverse events, with heterogeneity in treatment effects among different age strata. Overall, the clear safety signal in favor of NOACs over warfarin was evident irrespective of age strata, being most marked in the most elderly. PMID: 31809694 [PubMed - as supplied by publisher]
Source: Chest - December 2, 2019 Category: Respiratory Medicine Authors: Chao TF, Chiang CE, Liao JN, Chen TJ, Lip GYH, Chen SA Tags: Chest Source Type: research

A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore
CONCLUSION: NOACs were associated with similar stroke and major bleeding rates as warfarin for NVAF.PMID:33381777 | DOI:10.47102/annals-acadmedsg.2020184
Source: Ann Acad Med Singapo... - December 31, 2020 Category: General Medicine Authors: Wen Jun Tiew Vivien Lx Wong Vern Hsen Tan Yong Chuan Tan Elena Ms Lee Source Type: research

Use of Non-Vitamin  K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
ConclusionsAmong patients with NVAF and six or more comorbid conditions, NOACs were associated with varying risk of stroke/SE and MB compared to warfarin and to each other. Rather than a “one drug fits all” approach, our results may be useful for appropriate OAC treatment for multimorbid patients.
Source: Advances in Therapy - May 7, 2021 Category: Drugs & Pharmacology Source Type: research

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
CONCLUSION: Dabigatran, rivaroxaban, and apixaban appear to be superior to warfarin in both efficacy and safety in Asians with non-valvular AF.PMID:33968307 | PMC:PMC8069517 | DOI:10.4330/wjc.v13.i4.82
Source: World Journal of Cardiology - May 10, 2021 Category: Cardiology Authors: Wei-Jia Li Paraschos Archontakis-Barakakis Leonidas Palaiodimos Dimitrios Kalaitzoglou Lazaros Tzelves Apostolos Manolopoulos Yu-Chiang Wang Stefanos Giannopoulos Robert Faillace Damianos G Kokkinidis Source Type: research